MX2024001979A - Anticuerpos anti-relacionado con el receptor tirosina quinasa (ryk) y usos de estos. - Google Patents
Anticuerpos anti-relacionado con el receptor tirosina quinasa (ryk) y usos de estos.Info
- Publication number
- MX2024001979A MX2024001979A MX2024001979A MX2024001979A MX2024001979A MX 2024001979 A MX2024001979 A MX 2024001979A MX 2024001979 A MX2024001979 A MX 2024001979A MX 2024001979 A MX2024001979 A MX 2024001979A MX 2024001979 A MX2024001979 A MX 2024001979A
- Authority
- MX
- Mexico
- Prior art keywords
- ryk
- antibodies
- tyrosine kinase
- receptor tyrosine
- inter alia
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234527P | 2021-08-18 | 2021-08-18 | |
| PCT/US2022/075147 WO2023023600A1 (en) | 2021-08-18 | 2022-08-18 | Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001979A true MX2024001979A (es) | 2024-07-09 |
Family
ID=85241071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001979A MX2024001979A (es) | 2021-08-18 | 2022-08-18 | Anticuerpos anti-relacionado con el receptor tirosina quinasa (ryk) y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250027945A1 (https=) |
| EP (1) | EP4387669A4 (https=) |
| JP (1) | JP2024535691A (https=) |
| KR (1) | KR20240046558A (https=) |
| CN (1) | CN117979997A (https=) |
| AU (1) | AU2022331476A1 (https=) |
| CA (1) | CA3229528A1 (https=) |
| IL (1) | IL310670A (https=) |
| MX (1) | MX2024001979A (https=) |
| TW (1) | TW202315894A (https=) |
| WO (1) | WO2023023600A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR028424A1 (es) * | 2000-05-10 | 2003-05-07 | Bayer Corp | Metodo para regular la angiogenesis utilizando proteina ryk |
| AU2003239248A1 (en) * | 2002-06-07 | 2003-12-22 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And | Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| CA2694055A1 (en) * | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| WO2017172733A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
-
2022
- 2022-08-18 TW TW111131081A patent/TW202315894A/zh unknown
- 2022-08-18 US US18/684,453 patent/US20250027945A1/en active Pending
- 2022-08-18 EP EP22859387.7A patent/EP4387669A4/en active Pending
- 2022-08-18 AU AU2022331476A patent/AU2022331476A1/en active Pending
- 2022-08-18 CN CN202280063891.8A patent/CN117979997A/zh active Pending
- 2022-08-18 KR KR1020247008339A patent/KR20240046558A/ko active Pending
- 2022-08-18 IL IL310670A patent/IL310670A/en unknown
- 2022-08-18 JP JP2024509394A patent/JP2024535691A/ja active Pending
- 2022-08-18 MX MX2024001979A patent/MX2024001979A/es unknown
- 2022-08-18 CA CA3229528A patent/CA3229528A1/en active Pending
- 2022-08-18 WO PCT/US2022/075147 patent/WO2023023600A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023023600A1 (en) | 2023-02-23 |
| US20250027945A1 (en) | 2025-01-23 |
| AU2022331476A1 (en) | 2024-02-22 |
| CA3229528A1 (en) | 2023-02-23 |
| EP4387669A4 (en) | 2025-06-25 |
| CN117979997A (zh) | 2024-05-03 |
| IL310670A (en) | 2024-04-01 |
| KR20240046558A (ko) | 2024-04-09 |
| JP2024535691A (ja) | 2024-10-02 |
| TW202315894A (zh) | 2023-04-16 |
| EP4387669A1 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| ES2525477T3 (es) | Anticuerpos anti-factor D humanizados | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| PH12022553257A1 (en) | Antibodies to tigit | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
| GEP20104991B (en) | Antibodies that bind interleukin-4 receptor | |
| AR075896A1 (es) | Anticuerpos anti-her (factor de crecimiento epidermico) | |
| AR075790A2 (es) | Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural) | |
| DE602006013029D1 (de) | Anti-egfr-antikörper | |
| PH12013500347A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| AR065496A1 (es) | Anticuerpos anti- il-23 r | |
| NZ598194A (en) | Anti-cmet antibody and its use for the detection and the diagnosis of cancer | |
| ZA202210626B (en) | Anti-cd137 constructs, multispecific antibody and uses thereof | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| EA200870208A1 (ru) | Конструкт однодоменного антитела | |
| PE20121494A1 (es) | Anticuerpos anti notch-1 | |
| WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof |